Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects: Prediction of Slow Enzyme–Inhibitor Complex Dissociation of a Short-Living and Very Long-Acting Inhibitor - Almeida, Luis; Rocha, José Francisco; Falcão, Amílcar; Nuno Palma, P.; Loureiro, Ana I.; Pinto, Roberto; Bonifácio, Maria João; Wright, Lyndon C.; Nunes, Teresa; Soares-da-Silva, Patrício (Clinical pharmacokinetics, 2013)
Keywords: Adolescent; Adult; Antiparkinson Agents - blood; Antiparkinson Agents - pharmacology; Antiparkinson Agents - urine; Biological and medical sciences; Catechol O-Methyltransferase - metabolism; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors - blood; Enzyme Inhibitors - pharmacology; Enzyme Inhibitors - urine; Erythrocytes - drug effects; Erythrocytes - enzymology; Food-Drug Interactions; General pharmacology; Humans; Internal Medicine; Male; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Models, Biological; Original Research Article; Oxadiazoles - blood; Oxadiazoles - pharmacology; Oxadiazoles - urine; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Young Adult; Single Oral Dose; Entacapone; Levodopa; Healthy Male Subject; Tolcapone; Human; Pharmacokinetic pharmacodynamic relationship; Catechol O-methyltransferase inhibitor; Healthy subject; Toxicity; Prediction; Opicapone; Inhibitor enzyme complex; Predictive factor